

Transcriptional Activation of Elephant Shark Mineralocorticoid Receptor by Corticosteroids, Progesterins and Spironolactone

Yoshinao Katsu^{1,2,*}, Satomi Kohno³, Kaori Oka¹, Xiaozhi Lin¹, Sumika Otake¹, Nisha E. Pillai⁴, Wataru Takagi⁵, Susumu Hyodo⁵, Byrappa Venkatesh⁴, Michael E. Baker^{6,*}

¹Graduate School of Life Science, Hokkaido University, Sapporo, Japan; ²Department of Biological Sciences, Hokkaido University, Sapporo, Japan; ³Department of Obstetrics and Gynecology, Medical University of South Carolina, and Marine Biomedicine and Environmental Science Center, Hollings Marine Laboratory, Charleston, SC, USA;

⁴Comparative Genomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore; ⁵Laboratory of Physiology, Atmosphere and Ocean Research Institute, University of Tokyo, Chiba, Japan; ⁶Division of Nephrology, Department of Medicine, University of California, San Diego, CA, USA

Correspondence:

ykatsu@sci.hokudai.ac.jp

mbaker@ucsd.edu


Summary. We report the first analysis of corticosteroid and progesterone activation of full-length mineralocorticoid receptor (MR) from elephant shark (*Callorhinchus milii*), a cartilaginous fish belonging to the oldest group of jawed vertebrates. Aldosterone, cortisol, 11-deoxycorticosterone, corticosterone, 11-deoxycortisol, progesterone and 19-norprogesterone had half-maximal responses (EC50s) below 1 nM for elephant shark MR, and hence, these steroids, including progesterone, are potential physiological mineralocorticoids. Aldosterone, the physiological mineralocorticoid in humans and other terrestrial vertebrates, is not found in cartilaginous or ray-finned fishes. Progesterone is a precursor for corticosteroids that activate elephant shark MR, suggesting that progesterone was an ancestral ligand for the MR. Progesterone does not activate human, amphibian or alligator MRs indicating that progesterone activation of the MR was lost during the transition to terrestrial vertebrates. RNA-seq analysis finds strong MR expression in elephant shark ovary and testis, in which progesterone-activated MR may have novel functions.

34 **Introduction**

35 The mineralocorticoid receptor (MR) belongs to the nuclear receptor family, a large
36 and diverse group of transcription factors that also includes receptors for glucocorticoids
37 (GR), progestins (PR) androgens (AR) and estrogens (ER) (1, 2). Sequence analysis
38 revealed that the MR and GR are closely related (3); phylogenetic analysis indicates that MR
39 and GR evolved from a corticosteroid receptor (CR) that was present in jawless vertebrates,
40 such as lamprey and hagfish (4-7). A distinct mineralocorticoid receptor (MR) first appears
41 in cartilaginous fishes (Chondrichthyes), the oldest group of extant jawed vertebrates
42 (gnathostomes) that diverged from bony vertebrates about 450 million years and are a crucial
43 group in understanding the origin and evolution of jawed vertebrate morphology and
44 physiology (8, 9). Like mammals, cartilaginous fishes contain the full complement of
45 adrenal and sex steroid receptors: AR, ER, GR, MR and PR (1, 2, 4, 10).

46 Aldosterone (Aldo) is the physiological activator of transcription of human MR in
47 epithelial tissues, such as the kidney distal collecting tubules and the colon, in which the MR
48 regulates electrolyte homeostasis (6, 11-14). The MR also is found in brain, heart, aorta,
49 lung, liver, spleen, adipose tissue, testis, breast and ovary (12-18). The physiological
50 function of the MR in these tissues is still being elucidated.

51 The MR and other steroid receptors have a characteristic modular structure consisting
52 of an N-terminal domain (NTD) (domains A and B), a central DNA-binding domain (DBD)
53 (domain C), a hinge domain (D) and a C-terminal ligand-binding domain (LBD) (domain E)
54 (2, 4, 19-21) (Figure 1). The E domain alone is competent to bind steroids (4, 19, 22-24).
55 Interactions between the NTD (A/B domains) and the LBD and coactivators are important
56 regulators of transcriptional activation of mammalian MRs (25-32) and fish MRs (31-33).
57 Moreover, GAL-DBD-hinge-LBD constructs of zebrafish MR have different responses to
58 progestins and some corticosteroids than do GAL-DBD-hinge-LBD constructs of human,
59 chicken, alligator and *Xenopus* MRs (32).



60

61 **Figure 1. Comparison of domains in elephant shark MR with vertebrate MRs.** MRs from elephant
62 shark (shark), zebrafish, coelacanth, *Xenopus* (frog), chicken and human are compared. The functional
63 A/B domain to E domains are schematically represented with the numbers of amino acid residues and the
64 percentage of amino acid identity is depicted. GenBank accession numbers: elephant shark MR
65 (XP_007902220), zebrafish MR (NP_001093873), coelacanth MR (XP_014348128), *Xenopus*
66 (NP_001084074), chicken (ACO37437), human MR (NP_000892).

67

68 The timing of the evolution of this difference between full-length and truncated MRs
69 in ray-finned fishes and terrestrial vertebrates, as well as expression of the MR in
70 non-epithelial tissues is not known. Also unresolved is the identity of the ancestral
71 mineralocorticoid in cartilaginous fishes and the current mineralocorticoid in ray-finned fish
72 because aldosterone (Aldo), the physiological mineralocorticoid in terrestrial vertebrates, is
73 not found in cartilaginous fishes or ray-finned fishes. Aldo first appears in lobe-finned fish
74 (34), the forerunners of terrestrial vertebrates (35). Thus, the identity of the physiological
75 mineralocorticoid in cartilaginous fishes and ray-finned fishes is not established, although
76 cortisol and 11-deoxycorticosterone have been proposed (36-41).

77 Complicating the identity of the physiological mineralocorticoid in cartilaginous and
 78 ray-finned fishes is evidence that progesterone (Prog) and 19-norprogesterone (19norProg),
 79 along with spironolactone (Spiron) (Figure 2), are transcriptional activators of several
 80 ray-finned fish MRs (21, 33, 40), including zebrafish MR (42), and of chicken MR (32). In
 81 contrast, these steroids are antagonists for human MR (22, 24, 43), alligator MR and *Xenopus*
 82 MR (32). Ray-finned fish MRs and chicken MR differ in their response to Prog, 19norProg
 83 and Spiron, raising the question of whether the response to progestins and Spiron evolved in
 84 ray-finned fish before or after the divergence of ray-finned fish from the lobe-finned fish
 85 lineage that led to tetrapods.

86 Transcriptional activation by corticosteroids and other 3-ketosteroids of a full-length
 87 cartilaginous fish MR, which is the physiological MR, has not been investigated. Only
 88 truncated skate MR (44), consisting of the GAL4 DBD fused to the D domain and E domain
 89 of the MR (MR-LBD) has been studied for its response to corticosteroids. Carroll et al.
 90 found that aldosterone (Aldo), corticosterone, 11-deoxycorticosterone, and cortisol (Figure 2)
 91 are transcriptional activators of truncated skate MR.

92
 93
 94
 95
 96
 97




Figure 2. Structures of steroids that are ligands for the MR. Aldo, 11-deoxycorticosterone and S are physiological mineralocorticoids in terrestrial vertebrates (4, 6, 12, 45). S is both a mineralocorticoid and a glucocorticoid in lamprey (4, 46) and a glucocorticoid in ray-finned fish (47). Cortisol is a physiological glucocorticoid in terrestrial vertebrates and ray-finned fish (4, 10, 48-50). corticosterone is a glucocorticoid in rats and mice (4). Aldo, 11-deoxycorticosterone, cortisol, corticosterone and Prog have a similar high affinity for human MR (3, 51-53). Prog, 19norProg, 17OH-Prog and Spiron are antagonists for human MR (21, 43, 51) and rat MR (54, 55). Prog, 19norProg, and Spiron are agonists for fish MRs (21, 33, 40). 19norProg is a weak agonist for rat MR (56, 57).

Elephant shark MR is an attractive receptor to study early events in the evolution of mechanisms for regulating MR transcription because genomic analyses reveal that elephant shark genes are evolving slowly (9), making their genes windows into the past. Thus, we decided to investigate transcriptional activation by Aldo, 11-deoxycorticosterone, corticosterone, 11-deoxycortisol, cortisol, Prog, 19norProg, 17-hydroxyprogesterone (17OH-Prog) and Spiron of full-length and truncated elephant shark MR. Interestingly, all 3-ketosteroids, including progesterone, had EC50s of 1 nM or lower for full-length elephant shark MR. Transcriptional activation by Prog, 19norProg and Spiron of truncated elephant shark MR resembled that of zebrafish MR and not chicken MR, indicating that progestin activation of MR is an ancestral response, conserved in ray-finned fish, lost in *Xenopus*, alligator and human MRs, and distinct from activation of chicken MR, which arose independently. We also performed RNA-seq analysis of elephant shark MR and find widespread expression of MR in various elephant shark organs (gill, kidney, heart, intestine, liver, spleen, brain), with strong MR expression in ovary and testis, which are likely targets for Prog, suggesting a role for Prog-MR complexes in elephant shark reproduction, as well as in some other functions in other MR-containing organs. Indeed, our data suggest that Prog or a related progestin may have been one of the ancestral mineralocorticoids. Elephant shark RNA-seq analysis also indicates that expression of human MR in diverse organs, such as brain, heart, liver, spleen, ovary and testis, evolved in an ancestral cartilaginous fish.

Results

Functional domains of elephant shark MR and other vertebrate MRs.

In Figure 1, we compare the functional domains of elephant shark MR to selected vertebrate MRs. Elephant shark MR and human MR have 92% and 67% identity in DBD and LBD, respectively. Interestingly, elephant shark MR has similar conservation to the DBD (91-92%) and LBD (64-69%) of other MRs. The A, B and D domains of elephant shark MR and other MRs are much less conserved.

Transcriptional activation of full-length and truncated elephant shark MR by corticosteroids, progestins and spironolactone.

We screened a panel of steroids at 0.1 nM and 1 nM for transcriptional activation of full-length and truncated elephant shark MR. Aldo, cortisol, corticosterone, 11-deoxycorticosterone and 11-deoxycortisol were strong activators of full-length elephant

shark MR (Figure 3A) indicating that elephant shark MR has broad specificity for corticosteroids. Interestingly, at these low concentrations, all progestins and Spiron are transcriptional activators of full-length elephant shark MR, with 19-norProg having the strongest activity and 17OHProg having the weakest activity (Figure 3A). In parallel experiments, truncated elephant shark MR, lacking the A/B domain and containing a GAL4-DBD instead of the MR DBD, retained a strong response to all corticosteroids and 19nor Prog (Figure 3B). Prog and Spiron had significant, but reduced activity, while 17OH-Prog had little activity for truncated elephant shark MR.




Figure 3. Transcriptional activation of elephant shark MR by 3-ketosteroids. Full length and truncated elephant shark MR were expressed in HEK293 cells with an MMTV-luciferase reporter. **A.** Full length elephant shark MR. Cells were treated with 0.1 nM or 1.0 nM Aldo, cortisol, corticosterone, 11-deoxycorticosterone, 11-deoxycortisol, Prog, 19norProg (19NP), 17OH-Prog, Spiron or vehicle alone (DMSO). **B.** Truncated elephant shark MR. Cells were treated with 0.1 nM or 1.0 nM Aldo, cortisol, corticosterone, 11-deoxycorticosterone, 11-deoxycortisol, Prog, 19norProg (19NP), 17OH-Prog or Spiron or vehicle alone (DMSO). Results are expressed as means \pm SEM, n=3. Y-axis indicates fold-activation compared to the activity of control vector with vehicle (DMSO) alone as 1.

EC₅₀ values for steroid activation of elephant shark MR

Concentration-dependence of transcriptional activation of full length elephant shark MR by corticosteroids (Aldo, cortisol, corticosterone, 11-deoxycorticosterone, 11-deoxycortisol) is shown in Figure 4A and by progestins (Prog, 19norProg, 17OH-Prog) and Spiron in Figure 4B. The corresponding concentration-dependent curves for truncated elephant shark MR are shown in Figures 4C and 4D, respectively. Table 1 summarizes the EC₅₀s of corticosteroids for full-length and truncated elephant shark MR. Table 1 also contains, for comparison, previously determined EC₅₀s of corticosteroids for full-length and truncated human, chicken, alligator, *Xenopus* and zebrafish MRs (32) and skate MR (44).




Figure 4. Concentration-dependent transcriptional activation of full-length and truncated elephant shark MR (shark MR) by 3-ketosteroids. Full length and truncated elephant shark MR (shark MR) were expressed in HEK293 cells with an MMTV-luciferase reporter. Full-length elephant shark MR (shark MR) (A) and (C) and truncated elephant shark MR (shark MR) (B) and (D). (A), (B) Aldo, cortisol, corticosterone, 11deoxycorticosterone or 11-deoxycortisol. (C), (D) Aldo, Prog, 19norProg (19nor-P), 17OH-Prog (17OH-P) or Spiron. Cells transfected with elephant shark MR were treated with increasing concentrations of cortisol, corticosterone, Aldo,

11deoxycorticosterone, 11-deoxycortisol, Prog, 19norProg, 17OH-Prog, Spiron or vehicle alone
(DMSO). Y-axis indicates fold-activation compared to the activity of control vector with vehicle
(DMSO) alone as 1.

Table 1. Corticosteroid activation of full-length MR and GAL4-DBD-MR-LBD


MR	Aldo	B	F	DOC	S
	EC50 (M)	EC50 (M)	EC50 (M)	EC50 (M)	EC50 (M)
Elephant shark Full	1.1 x 10 ⁻¹⁰	1.7 x 10 ⁻¹⁰	4.6 x 10 ⁻¹⁰	6.3 x 10 ⁻¹¹	1.1 x 10 ⁻¹⁰
	100%	101%	114%	83%	83%
Elephant shark LBD	3.7 x 10 ⁻¹¹	9.9 x 10 ⁻¹¹	1.9 x 10 ⁻¹⁰	2.4 x 10 ⁻¹¹	6.8 x 10 ⁻¹¹
	100%	90%	79%	81%	77%
¹ Skate LBD	7 x 10 ⁻¹¹	1 x 10 ⁻¹⁰	1 x 10 ⁻⁹	3 x 10 ⁻¹¹	2.2 x 10 ⁻⁸
² Human Full	2.7 x 10 ⁻¹⁰	1.2 x 10 ⁻⁹	5.5 x 10 ⁻⁹	4.2 x 10 ⁻¹⁰	3.6 x 10 ⁻⁹
	100%	119%	133%	74%	42%
² Human LBD	2.8 x 10 ⁻¹⁰	5.9 x 10 ⁻¹⁰	3. x 10 ⁻⁹	1.8 x 10 ⁻⁹	#-
	100%	95%	74%	44%	*8%
² Chicken Full	6.2 x 10 ⁻¹¹	5.1 x 10 ⁻¹¹	2.8 x 10 ⁻¹⁰	3.4 x 10 ⁻¹¹	6.7 x 10 ⁻¹⁰
	100%	109%	128%	110%	112%
² Chicken LBD	1.3 x 10 ⁻¹⁰	1.6 x 10 ⁻¹⁰	6.9 x 10 ⁻¹⁰	1.7 x 10 ⁻¹⁰	4.7 x 10 ⁻⁹
	100%	92%	75%	92%	36%
² Alligator-Full	2.8x 10 ⁻¹⁰	3.6 x 10 ⁻¹⁰	6.9x 10 ⁻⁹	2.3 x 10 ⁻¹⁰	2.7 x 10 ⁻⁹
	100%	138%	176%	85%	45%
² Alligator LBD	3.5 x 10 ⁻¹⁰	3.8 x 10 ⁻¹⁰	2.3 x 10 ⁻⁹	5.2 x 10 ⁻¹⁰	#-
	100%	88%	68%	51%	*8%
² Xenopus Full	4.6 x 10 ⁻¹⁰	6.2 x 10 ⁻¹⁰	1.1 x 10 ⁻⁸	7.6 x 10 ⁻¹⁰	9.1 x 10 ⁻⁹
	100%	105%	126%	59%	31%
² Xenopus-LBD	1.5 x 10 ⁻⁹	1.9 x 10 ⁻⁹	1.2 x 10 ⁻⁸	#-	#-
	100%	74%	37%	*10%	*6%
² Zebrafish Full	8.2 x 10 ⁻¹¹	3.0 x 10 ⁻¹⁰	4.4 x 10 ⁻¹⁰	6.3 x 10 ⁻¹¹	4.0 x 10 ⁻¹⁰
	100%	112%	123%	103%	94%
² Zebrafish LBD	2.7 x 10 ⁻¹¹	1.5 x 10 ⁻¹⁰	3.1 x 10 ⁻¹⁰	1.0 x 10 ⁻¹⁰	9.1 x 10 ⁻¹⁰
	100%	96%	77%	99%	67%

¹ (44)

² (32) doi:doi: <https://doi.org/10.1101/151233>)

183 # Curve did not saturate.
 184 (%) Relative induction to Aldosterone induced activation.
 185 * Relative induction at 1 μ M compared to Aldo.

186
 187 Previously we reported that progestins and Spiron are transcriptional activators of
 188 full-length chicken and zebrafish MRs and truncated zebrafish MR (32). However, EC50
 189 values of progestins and Spiron for these MR were not determined. We have remedied this
 190 omission and report their EC50 values in Table 2 and Figure 5, for comparison with
 191 full-length and truncated elephant shark MR.
 192



193
 194 **Figure 5. Concentration-dependent transcriptional activation of full-length and truncated**
 195 **chicken and zebrafish MR by progestins and Spironolactone.** HEK293 cells transfected with
 196 chicken and zebrafish MR were treated with increasing concentrations of Prog, 19norProg,
 197 17OH-Prog or Spiron. Full-length chicken MR (A) and zebrafish MR (B) and truncated chicken MR
 198 (C) and zebrafish MR (D). Y-axis indicates fold-activation compared to the activity of control vector
 199 with vehicle (DMSO) alone as 1.

Table 2. EC50 values for progestin and spironolactone activation of full-length and GAL4-DBD-MR-LBD constructs of elephant shark, zebrafish and chicken MR

MR	Aldo	Prog	17OH-Prog	19norProg	Spiron
Elephant shark Full	1.1 x 10⁻¹⁰	2.7 x 10⁻¹⁰	1.4 x 10⁻⁹	4.3 x 10⁻¹¹	5.5 x 10⁻¹⁰
	100%	43%	25%	84%	45%
Elephant shark LBD	3.7 x 10⁻¹¹	4.8 x 10⁻¹⁰	2.9 x 10⁻⁹	1.8 x 10⁻¹¹	4.2 x 10⁻¹⁰
	100%	40%	26%	98%	53%
²Zebrafish Full	8.2 x 10⁻¹¹	2.4 x 10⁻⁹	1.8 x 10⁻⁸	9.4 x 10⁻¹⁰	3.8 x 10⁻⁹
	100%	77%	44%	83%	54%
²Zebrafish LBD	2.7 x 10⁻¹¹	9.8 x 10⁻⁸	#-	6.4 x 10⁻⁸	#-
	100%	122%	*24%	122%	*73%
²Chicken Full	6.2 x 10⁻¹¹	7.1 x 10⁻¹⁰	2.9 x 10⁻⁸	6.8 x 10⁻¹⁰	5.1 x 10⁻⁹
	100%	62%	15%	68%	30%
²Chicken LBD	1.3 x 10⁻¹⁰	#-	#-	#-	#-
	100%	*21%	-	*29%	-

² (32) doi:doi: <https://doi.org/10.1101/151233>)# Curve did not saturate.

(%) Relative induction to Aldosterone induced activation.

* Relative induction at 1 μM compared to Aldo.

RNA-seq analysis of elephant shark MR

We examined expression of level of elephant shark MR gene in 10 tissues based on RNA-seq data (Figure 6). The MR gene was found to express widely in all tissues, including gills and kidney, two traditional mineralocorticoid-responsive tissues. Interestingly there was considerably higher expression in the ovary and testis, the two reproductive tissues analyzed.




Figure 6. Expression level of MR gene in 10 tissues of elephant shark estimated based on RNA-seq data. Transcript abundances are shown in terms of normalized counts called Fragments per kilobase of exon per million fragments mapped (FPKM) (58). FPKM is estimated by normalizing gene length followed by normalizing for sequencing depth.

RNA-seq analysis of human MR

RNA-seq analysis of human MR (59) (Figure 7) reveals that the MR is expressed in kidney, colon, brain, heart, liver, ovary, spleen and testis. This diverse pattern of expression is similar to that of elephant shark MR.




Figure 7. Expression level of human MR based on RNA-seq data. Transcript abundances are shown in terms of normalized counts called Reads Per Kilobase of transcript per Million mapped reads (RPKM) (59).

Discussion

Cartilaginous fish, including elephant sharks, occupy a key position in the evolution of vertebrates as an out-group to ray-finned fish, the largest group of extant vertebrates, and the lobe-finned fish, which are the forerunners of terrestrial vertebrates. Importantly, the elephant shark genome is evolving slowly (9), making it attractive for studying ancestral proteins, including the MR, which first appears as a distinct MR ortholog in cartilaginous fish (5, 6, 10, 44).

This is the first report of transcriptional activation of a full-length cartilaginous fish MR by a panel of five corticosteroids and Prog, 19norProg, 17OH-Prog and Spiron. Full-length elephant shark MR has EC50s below 1 nM for five corticosteroids, (Figure 4, Table 1) including Aldo, a steroid that has not been found in cartilaginous fish. Prog, 19norProg and Spiron also have sub-nM EC50s for full-length elephant shark MR. In addition to their low EC50s, all of these corticosteroids and 19norProg have similar fold activation of transcription of full-length MR (Figure 4). Thus, several corticosteroids, as well as 19norProg and Prog, are potential physiological mineralocorticoids for elephant shark MR.

Compared to full-length elephant shark MR, the EC50s of all five corticosteroids and 19norProg are lower for its truncated MR, while the EC50 for Spiron is slightly lower, and the EC50s for Prog and 17OH-Prog are about 2-fold higher (Table 1, Table 2). Compared to fold activation by Aldo, the responses to 11-deoxycorticosterone, S, Prog and 17OH-Prog are similar for full-length and truncated elephant shark MR. However, the relative responses to corticosterone and cortisol of truncated elephant shark MR are 10% and 35% lower, respectively, (Figure 4, Table 1) and for 19norProg and Spiron, 14% and 8% higher respectively, than for full-length elephant shark MR (Figure 4, Table 2). Regarding truncated skate MR, most of the EC50s of corticosteroids (44) are similar to that for elephant shark MR (Table 1). The exception is 11-deoxycortisol, which has over 200-fold higher EC50 for skate MR than for elephant shark MR.

Corticosteroid and progestin activation of full-length and truncated elephant shark, terrestrial vertebrate and zebrafish MRs

Comparison of transcriptional activation by corticosteroids and progestins of full-length and truncated elephant shark MR with full-length and truncated human, chicken, alligator, *Xenopus* and zebrafish MRs (Table 1) provides insights into the evolution of regulation of steroid-mediated transcription of these MRs by allosteric interactions between the NTD/DBD and LBD. Like elephant shark MR, truncated terrestrial vertebrate MRs and zebrafish MR have similar EC50s for Aldo, corticosterone and cortisol as their full-length

counterparts (Table 1). However, the response of truncated human, alligator and *Xenopus* MRs to 11-deoxycortisol did not saturate at 1 μ M, preventing us from determining the EC₅₀ and explaining the low fold activation by S (Table 1). Interestingly, truncated chicken and zebrafish MRs, which are activated by progestins, have nM EC₅₀s for 11-deoxycortisol, although fold activation by 11-deoxycortisol is lower than that of Aldo. The similar activity of truncated human, alligator and *Xenopus* MRs to Aldo, corticosterone and cortisol indicates that allosteric interactions between the NTD and LBD are steroid-selective. Overall, it appears that corticosteroid activation, especially by 11-deoxycortisol, of elephant shark MR is less sensitive to the loss of NTD/DBD than are human, chicken, alligator and *Xenopus* MRs.

Progestin activation of full-length and truncated chicken and zebrafish MRs

Transcriptional activation by progestins of chicken and zebrafish MRs differs from that of elephant shark MR, especially for their truncated MRs. Although Prog, 19norProg and Spiron have nM EC₅₀s for transcriptional activation of full-length chicken and zebrafish MRs, at 1 μ M Prog 19norProg and Spiron transcriptional activation of truncated chicken MR did not saturate, and at 1 μ M Spiron transcriptional activation of zebrafish MR did not saturate (Figure 5, Table 2). Fold activation compared to Aldo by all progestins and Spiron is substantially lower for truncated chicken MR and for Spiron activation of zebrafish MR. However, Prog and 19norProg have EC₅₀s of 98 nM and 64 nM, respectively, for truncated zebrafish MR. In this respect, truncated zebrafish MR is closer to truncated elephant shark MR than is truncated chicken MR. These data suggest that transcriptional activation by progestins of chicken MR appears to have evolved independently in terrestrial vertebrates.

Progestins may be mineralocorticoids in cartilaginous fishes

Prog is a precursor for the synthesis of the other corticosteroids (5, 60). Two parsimonious metabolites of progesterone are 11-deoxycorticosterone (21-hydroxyprogesterone) and 19norProg (Figure 2), which have EC₅₀s, 0.063 nM and 0.043 nM, respectively, for elephant shark MR. These are the two lowest EC₅₀s among the tested steroids. Moreover, 19norProg evokes a stronger response from elephant shark MR than Aldo (Figure 4A, B). C19 demethylase activity has been found in mammalian kidney (56). If C19 demethylase is present in elephant shark, then 19norProg needs to be considered as a potential physiological mineralocorticoid.

The strong response to 19norProg is interesting because *in vivo* studies in rats revealed that 19norProg is at least a 100-fold weaker MR agonist than Aldo (56), while in transfected cells, at 1 nM, 19norProg is an antagonist (21, 43). Unexpectedly, compared to Aldo, 19norAldo has less than 1% binding affinity for rat MR (61) indicating that the mechanism by which C19 demethylation of Prog increases this steroid's transcriptional

activity for elephant shark MR is likely to be complex.

We propose that transcriptional activation of elephant shark MR by 19norProg, as well as by Prog and Spiron, can be explained by a mechanism based on Geller et al.'s (43) discovery that S810L human MR mutant is transcriptionally activated by 1 nM Prog, 19norProg, and Spiron, unlike wild-type human MR, in which these steroids are MR antagonists. Geller et al. used a 3D model of S810L MR and transcriptional analysis of a series of mutations at Ser-810 (helix 5) and Ala-773 (helix 3) to propose that a van der Waals contact between Leu-810 and Ala-773 was sufficient for transcriptional activation of S810L MR by progestins. In Figure 3C of Geller et al. (43), the human S810M mutant was activated by 19norProg. Elephant shark MR and skate MR contain a methionine at this position and an alanine corresponding to Ala-773 (Figure 8). Based on Geller et al.'s model, we propose that transcriptional activation of elephant shark MR by 19norProg is due to a van der Waals contact between Met-782 (helix 5) and Ala-745 (helix 3), which stabilizes the A ring of 19norProg, promoting transcriptional activation.




Figure 8. Alignment of elephant shark MR to Serine-810 and Alanine-773 in helices 3-5 in human MR.

Elephant shark MR and skate MR contain a methionine corresponding to human Ser-810 and an alanine corresponding to Ala-773. Lamprey CR and hagfish CR also contain a corresponding methionine, as well as a cysteine corresponding to Ala-773. Human Ser-810 and Ala-773 are conserved in coelacanths, terrestrial vertebrate and ray-finned fish MRs. Amino acids that are identical to amino acids in human MR are denoted by (-).

Our results indicate that progestin activation of the MR is an ancient response. The timing of evolution of Prog as an MR antagonist is not known. One necessary, but not sufficient event, is the evolution in helix 5 of a serine corresponding to serine-810 in human

MR. This occurs in coelacanth MR, which contains Ser-816, corresponding to human MR Ser-810 (Figure 8) and to elephant shark MR Met-782. This mutation in coelacanth MR would be expected to eliminate the proposed van der Waals contact between helix 5 and helix 3, leading to antagonist activity of Prog in some terrestrial vertebrate MRs (32). However, a serine corresponding to Ser-810 in human MR also is present in chicken MR and ray-finned fish MRs (Figure 8), indicating another mechanism is involved in Prog activation of the MR in these vertebrates.

Role for elephant shark MR in reproductive physiology

The evidence from RNA-seq analysis of high MR expression in ovary and testis (Figure 6) suggests that a Prog-MR complex is important in reproductive responses in elephant shark. Of course, Prog also acts as a reproductive steroid in ovary and testis via transcriptional activation of the PR (62, 63). Based on evidence that Prog activates the MR in several ray-finned fishes (21, 33, 40, 42), a Prog-MR complex also may activate transcription in reproductive tissues and other organs in ray-finned fish, as well as cartilaginous fish.

RNA-seq analysis also finds MR expression in elephant shark gills and kidneys (Figure 6), two classical targets for MR regulation of electrolyte transport (6). RNA-seq analysis also identifies MR expression in elephant shark heart and brain, two other organs in which corticosteroids have important physiological actions via the MR (15-17, 64-66). Indeed, RNA seq analysis of elephant shark MR indicates that expression the MR in diverse organs was conserved during the descent from cartilaginous fishes to humans.

Materials and Methods

Chemical reagents

Aldo, cortisol, corticosterone, 11-deoxycorticosterone, 11-deoxycortisol, Prog, 19norProg, 17OH-Prog and Spiron were purchased from Sigma-Aldrich. For reporter gene assays, all hormones were dissolved in dimethylsulfoxide (DMSO); the final DMSO concentration in the culture medium did not exceed 0.1%.

Construction of plasmid vectors

The full-coding regions from elephant shark MR were amplified by PCR with KOD DNA polymerase. The PCR products were gel-purified and ligated into pcDNA3.1 vector (Invitrogen) for the full-coding region or pBIND vector for D-E domains {Oka, 2013 #48}.

RNA-sequence analysis

The RNA-seq reads from following tissues of elephant shark were down-loaded from the Sequence Read Archive database of NCBI (accession number SRA054255): brain,

gills, heart, intestine, kidney, liver, muscle, ovary, spleen, and testis. For each tissue, sequences were assembled *de novo* using Trinity, version r2013-08-14 {Grabherr, 2011 #396}.

Gene Expression Analyses

To determine the expression level of MR genes, we performed abundance estimation of transcripts from the afore mentioned 10 tissues. Trinity transcripts from all ten tissues and full-length cDNA sequence of the MR gene were combined together and clustered using CD-HITv4.6.1 at 100% identity {Li, 2006 #394}. RNA-seq reads from each of the ten tissues was independently aligned to the clustered transcript sequences and abundance of MR gene transcripts was estimated by RSEMv1.2.25 (58) which uses bowtie2.2.6 for aligning (67). Transcript abundances were measured in terms of normalized counts called Fragments per kilobase of exon per million fragments mapped (FPKM) (58). FPKM is estimated by normalizing the gene length followed by normalizing for sequencing depth.

Transactivation Assay and Statistical Methods

Transfection and reporter assays were carried out in HEK293 cells, as described previously (68, 69). All experiments were performed in triplicate. The values shown are mean \pm SEM from three separate experiments, and dose-response data and EC50 were analyzed using GraphPad Prism. Comparisons between two groups were performed using *t*-test, and all multi-group comparisons were performed using one-way ANOVA followed by Bonferroni test. $P < 0.05$ was considered statistically significant.

Acknowledgments: K.O. was supported by the Japan Society for the Promotion of Science (JSPS) Research Fellowships for Young Scientists. This work was supported in part by Grants-in-Aid for Scientific Research 23570067 and 26440159 (YK) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. M.E.B. was supported by Research fund #3096. BV was supported by the Biomedical Research Council of A*STAR, Singapore.

Author contributions: Y.K., S.K., K.O., X.L., S.O. and N.E.P. carried out the research. Y.K. and S.K. analyzed data. W.T. and S.H. aided in the collection of animals. NEP assembled and analyzed RNAseq data. Y.K. and M.E.B. conceived and designed the experiments. Y.K., M.E.B. and B.V. wrote the paper. All authors gave final approval for publication.

Declaration of interests: We have no competing interests.

References

1. M. E. Baker, D. R. Nelson, R. A. Studer, Origin of the response to adrenal and sex steroids: Roles of promiscuity and co-evolution of enzymes and steroid receptors. *J Steroid Biochem Mol Biol* **151**, 12-24 (2015).
2. R. M. Evans, The steroid and thyroid hormone receptor superfamily. *Science* **240**, 889-895 (1988).
3. J. L. Arriza, C. Weinberger, G. Cerelli, T. M. Glaser, B. L. Handelin, D. E. Housman, R. M. Evans, Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. *Science* **237**, 268-275 (1987).
4. M. E. Baker, J. W. Funder, S. R. Kattoula, Evolution of hormone selectivity in glucocorticoid and mineralocorticoid receptors. *J Steroid Biochem Mol Biol* **137**, 57-70 (2013).
5. M. E. Baker, Y. Katsu, 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Evolution of the mineralocorticoid receptor: sequence, structure and function. *J Endocrinol* **234**, T1-T16 (2017).
6. B. C. Rossier, M. E. Baker, R. A. Studer, Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. *Physiological reviews* **95**, 297-340 (2015).
7. J. W. Thornton, Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. *Proc Natl Acad Sci U S A* **98**, 5671-5676 (2001).
8. J. G. Inoue, M. Miya, K. Lam, B. H. Tay, J. A. Danks, J. Bell, T. I. Walker, B. Venkatesh, Evolutionary origin and phylogeny of the modern holocephalans (Chondrichthyes: Chimaeriformes): a mitogenomic perspective. *Molecular biology and evolution* **27**, 2576-2586 (2010).
9. B. Venkatesh, A. P. Lee, V. Ravi, A. K. Maurya, M. M. Lian, J. B. Swann, Y. Ohta, M. F. Flajnik, Y. Sutoh, M. Kasahara, S. Hoon, V. Gangu, S. W. Roy, M. Irimia, V. Korzh, I. Kondrychyn, Z. W. Lim, B. H. Tay, S. Tohari, K. W. Kong, S. Ho, B. Lorente-Galdos, J. Quilez, T. Marques-Bonet, B. J. Raney, P. W. Ingham, A. Tay, L. W. Hillier, P. Minx, T. Boehm, R. K. Wilson, S. Brenner, W. C. Warren, Elephant shark genome provides unique insights into gnathostome evolution. *Nature* **505**, 174-179 (2014).
10. J. T. Bridgham, S. M. Carroll, J. W. Thornton, Evolution of hormone-receptor complexity by molecular exploitation. *Science* **312**, 97-101 (2006).

- 428 11. J. W. Funder, Aldosterone and mineralocorticoid receptors: a personal reflection.
429 *Molecular and cellular endocrinology* **350**, 146-150 (2012).
- 430 12. U. A. Hawkins, E. P. Gomez-Sanchez, C. M. Gomez-Sanchez, C. E. Gomez-Sanchez,
431 The ubiquitous mineralocorticoid receptor: clinical implications. *Curr Hypertens Rep*
432 **14**, 573-580 (2012).
- 433 13. L. Martinerie, M. Munier, D. Le Menuet, G. Meduri, S. Viengchareun, M. Lombes,
434 The mineralocorticoid signaling pathway throughout development: expression,
435 regulation and pathophysiological implications. *Biochimie* **95**, 148-157 (2013).
- 436 14. F. Jaisser, N. Farman, Emerging Roles of the Mineralocorticoid Receptor in
437 Pathology: Toward New Paradigms in Clinical Pharmacology. *Pharmacological*
438 *reviews* **68**, 49-75 (2016).
- 439 15. E. P. Gomez-Sanchez, Mineralocorticoid receptors in the brain and cardiovascular
440 regulation: minority rule? *Trends Endocrinol Metab* **22**, 179-187 (2011).
- 441 16. J. J. DuPont, I. Z. Jaffe, 30 YEARS OF THE MINERALOCORTICOID RECEPTOR:
442 The role of the mineralocorticoid receptor in the vasculature. *J Endocrinol* **234**,
443 T67-T82 (2017).
- 444 17. M. Joels, E. R. de Kloet, 30 YEARS OF THE MINERALOCORTICOID
445 RECEPTOR: The brain mineralocorticoid receptor: a saga in three episodes. *J*
446 *Endocrinol* **234**, T49-T66 (2017).
- 447 18. T. J. Cole, M. J. Young, 30 YEARS OF THE MINERALOCORTICOID RECEPTOR:
448 Mineralocorticoid receptor null mice: informing cell-type-specific roles. *J Endocrinol*
449 **234**, T83-T92 (2017).
- 450 19. P. Huang, V. Chandra, F. Rastinejad, Structural overview of the nuclear receptor
451 superfamily: insights into physiology and therapeutics. *Annu Rev Physiol* **72**, 247-272
452 (2010).
- 453 20. F. Rastinejad, P. Huang, V. Chandra, S. Khorasanizadeh, Understanding nuclear
454 receptor form and function using structural biology. *Journal of molecular*
455 *endocrinology* **51**, T1-T21 (2013).
- 456 21. A. Sugimoto, K. Oka, R. Sato, S. Adachi, M. E. Baker, Y. Katsu, Corticosteroid and
457 progesterone transactivation of mineralocorticoid receptors from Amur sturgeon and
458 tropical gar. *Biochem J* **473**, 3655-3665 (2016).
- 459 22. J. Fagart, J. Huyet, G. M. Pinon, M. Rochel, C. Mayer, M. E. Rafestin-Oblin, Crystal
460 structure of a mutant mineralocorticoid receptor responsible for hypertension. *Nature*
461 *structural & molecular biology* **12**, 554-555 (2005).
- 462 23. Y. Li, K. Suino, J. Daugherty, H. E. Xu, Structural and biochemical mechanisms for

- 463 the specificity of hormone binding and coactivator assembly by mineralocorticoid
464 receptor. *Mol Cell* **19**, 367-380 (2005).
- 465 24. R. K. Bledsoe, K. P. Madauss, J. A. Holt, C. J. Apolito, M. H. Lambert, K. H. Pearce,
466 T. B. Stanley, E. L. Stewart, R. P. Trump, T. M. Willson, S. P. Williams, A
467 ligand-mediated hydrogen bond network required for the activation of the
468 mineralocorticoid receptor. *The Journal of biological chemistry* **280**, 31283-31293
469 (2005).
- 470 25. R. Rupprecht, J. L. Arriza, D. Spengler, J. M. Reul, R. M. Evans, F. Holsboer, K.
471 Damm, Transactivation and synergistic properties of the mineralocorticoid receptor:
472 relationship to the glucocorticoid receptor. *Molecular endocrinology (Baltimore, Md)*
473 **7**, 597-603 (1993).
- 474 26. F. M. Rogerson, P. J. Fuller, Interdomain interactions in the mineralocorticoid receptor.
475 *Molecular and cellular endocrinology* **200**, 45-55 (2003).
- 476 27. R. Kumar, G. Litwack, Structural and functional relationships of the steroid hormone
477 receptors' N-terminal transactivation domain. *Steroids* **74**, 877-883 (2009).
- 478 28. J. B. Pippal, Y. Yao, F. M. Rogerson, P. J. Fuller, Structural and functional
479 characterization of the interdomain interaction in the mineralocorticoid receptor. *Mol*
480 *Endocrinol* **23**, 1360-1370 (2009).
- 481 29. K. Fischer, S. M. Kelly, K. Watt, N. C. Price, I. J. McEwan, Conformation of the
482 mineralocorticoid receptor N-terminal domain: evidence for induced and stable
483 structure. *Mol Endocrinol* **24**, 1935-1948 (2010).
- 484 30. N. Faresse, Post-translational modifications of the mineralocorticoid receptor: How to
485 dress the receptor according to the circumstances? *J Steroid Biochem Mol Biol* **143**,
486 334-342 (2014).
- 487 31. P. J. Fuller, Novel interactions of the mineralocorticoid receptor. *Molecular and*
488 *cellular endocrinology* **408**, 33-37 (2015).
- 489 32. Y. Katsu, K. Oka, M. E. Baker, Evolution of steroid specificity in human, chicken,
490 alligator, frog and zebrafish mineralocorticoid receptors: Allosteric interactions affect
491 steroid specificity. *bioRxiv*, (2018).
- 492 33. J. B. Pippal, C. M. Cheung, Y. Z. Yao, F. E. Brennan, P. J. Fuller, Characterization of
493 the zebrafish (*Danio rerio*) mineralocorticoid receptor. *Molecular and cellular*
494 *endocrinology* **332**, 58-66 (2011).
- 495 34. J. M. P. Joss, D. E. Arnoldreed, R. J. Balment, The Steroidogenic Response to
496 Angiotensin-II in the Australian Lungfish, *Neoceratodus-Forsteri*. *J Comp Physiol B*
497 **164**, 378-382 (1994).

- 498 35. C. T. Amemiya, J. Alföldi, A. P. Lee, S. Fan, H. Philippe, I. Maccallum, I. Braasch, T.
499 Manousaki, I. Schneider, N. Rohner, C. Organ, D. Chalopin, J. J. Smith, M. Robinson,
500 R. A. Dorrington, M. Gerdol, B. Aken, M. A. Biscotti, M. Barucca, D. Baurain, A. M.
501 Berlin, G. L. Blatch, F. Buonocore, T. Burmester, M. S. Campbell, A. Canapa, J. P.
502 Cannon, A. Christoffels, G. De Moro, A. L. Edkins, L. Fan, A. M. Fausto, N. Feiner,
503 M. Forconi, J. Gamielien, S. Gnerre, A. Gnirke, J. V. Goldstone, W. Haerty, M. E.
504 Hahn, U. Hesse, S. Hoffmann, J. Johnson, S. I. Karchner, S. Kuraku, M. Lara, J. Z.
505 Levin, G. W. Litman, E. Mauceli, T. Miyake, M. G. Mueller, D. R. Nelson, A. Nitsche,
506 E. Olmo, T. Ota, A. Pallavicini, S. Panji, B. Picone, C. P. Ponting, S. J. Prohaska, D.
507 Przybylski, N. R. Saha, V. Ravi, F. J. Ribeiro, T. Sauka-Spengler, G. Scapigliati, S. M.
508 Searle, T. Sharpe, O. Simakov, P. F. Stadler, J. J. Stegeman, K. Sumiyama, D. Tabbaa,
509 H. Tafer, J. Turner-Maier, P. van Heusden, S. White, L. Williams, M. Yandell, H.
510 Brinkmann, J. N. Volff, C. J. Tabin, N. Shubin, M. Schartl, D. B. Jaffe, J. H.
511 Postlethwait, B. Venkatesh, F. Di Palma, E. S. Lander, A. Meyer, K. Lindblad-Toh,
512 The African coelacanth genome provides insights into tetrapod evolution. *Nature* **496**,
513 311-316 (2013).
- 514 36. M. E. Baker, Evolution of glucocorticoid and mineralocorticoid responses: go fish.
515 *Endocrinology* **144**, 4223-4225 (2003).
- 516 37. M. E. Baker, C. Chandsawangbhuwana, N. Ollikainen, Structural analysis of the
517 evolution of steroid specificity in the mineralocorticoid and glucocorticoid receptors.
518 *BMC Evol Biol* **7**, 24 (2007).
- 519 38. N. R. Bury, A. Sturm, Evolution of the corticosteroid receptor signalling pathway in
520 fish. *Gen Comp Endocrinol* **153**, 47-56 (2007).
- 521 39. T. Sakamoto, C. Mori, S. Minami, H. Takahashi, T. Abe, D. Ojima, M. Ogoshi, H.
522 Sakamoto, Corticosteroids stimulate the amphibious behavior in mudskipper:
523 potential role of mineralocorticoid receptors in teleost fish. *Physiol Behav* **104**,
524 923-928 (2011).
- 525 40. A. Sturm, N. Bury, L. Dengreville, J. Fagart, G. Flouriot, M. E. Rafestin-Oblin, P.
526 Prunet, 11-deoxycorticosterone is a potent agonist of the rainbow trout
527 (*Oncorhynchus mykiss*) mineralocorticoid receptor. *Endocrinology* **146**, 47-55
528 (2005).
- 529 41. H. Takahashi, T. Sakamoto, The role of 'mineralocorticoids' in teleost fish: relative
530 importance of glucocorticoid signaling in the osmoregulation and 'central' actions of
531 mineralocorticoid receptor. *Gen Comp Endocrinol* **181**, 223-228 (2013).
- 532 42. Y. Katsu, M. E. Baker, Progesterone activation of zebrafish mineralocorticoid receptor

- 533 may influence growth of some transplanted tumors. *Proc Natl Acad Sci U S A* **115**,
534 E2908-E2909 (2018).
- 535 43. D. S. Geller, A. Farhi, N. Pinkerton, M. Fradley, M. Moritz, A. Spitzer, G. Meinke, F.
536 T. Tsai, P. B. Sigler, R. P. Lifton, Activating mineralocorticoid receptor mutation in
537 hypertension exacerbated by pregnancy. *Science* **289**, 119-123 (2000).
- 538 44. S. M. Carroll, J. T. Bridgham, J. W. Thornton, Evolution of hormone signaling in
539 elasmobranchs by exploitation of promiscuous receptors. *Molecular biology and*
540 *evolution* **25**, 2643-2652 (2008).
- 541 45. P. J. Fuller, Y. Yao, J. Yang, M. J. Young, Mechanisms of ligand specificity of the
542 mineralocorticoid receptor. *J Endocrinol* **213**, 15-24 (2012).
- 543 46. D. A. Close, S. S. Yun, S. D. McCormick, A. J. Wildbill, W. Li, 11-deoxycortisol is a
544 corticosteroid hormone in the lamprey. *Proc Natl Acad Sci U S A* **107**, 13942-13947
545 (2010).
- 546 47. Y. Li, A. Sturm, P. Cunningham, N. R. Bury, Evidence for a divergence in function
547 between two glucocorticoid receptors from a basal teleost. *BMC Evol Biol* **12**, 137
548 (2012).
- 549 48. A. Sturm, L. Colliar, M. J. Leaver, N. R. Bury, Molecular determinants of hormone
550 sensitivity in rainbow trout glucocorticoid receptors 1 and 2. *Molecular and cellular*
551 *endocrinology* **333**, 181-189 (2011).
- 552 49. A. S. Arterbery, D. J. Fergus, E. A. Fogarty, J. Mayberry, D. L. Deitcher, W. Lee
553 Kraus, A. H. Bass, Evolution of ligand specificity in vertebrate corticosteroid
554 receptors. *BMC Evol Biol* **11**, 14 (2011).
- 555 50. N. R. Bury, The evolution, structure and function of the ray finned fish
556 (Actinopterygii) glucocorticoid receptors. *Gen Comp Endocrinol*, (2016).
- 557 51. R. Rupprecht, J. M. Reul, B. van Steensel, D. Spengler, M. Soder, B. Berning, F.
558 Holsboer, K. Damm, Pharmacological and functional characterization of human
559 mineralocorticoid and glucocorticoid receptor ligands. *Eur J Pharmacol* **247**, 145-154
560 (1993).
- 561 52. C. Hellal-Levy, B. Couette, J. Fagart, A. Souque, C. Gomez-Sanchez, M.
562 Rafestin-Oblin, Specific hydroxylations determine selective corticosteroid recognition
563 by human glucocorticoid and mineralocorticoid receptors. *FEBS Lett* **464**, 9-13
564 (1999).
- 565 53. O. Mani, L. G. Nashev, C. Livelo, M. E. Baker, A. Odermatt, Role of Pro-637 and
566 Gln-642 in human glucocorticoid receptors and Ser-843 and Leu-848 in
567 mineralocorticoid receptors in their differential responses to cortisol and aldosterone.

- 568 *J Steroid Biochem Mol Biol* **159**, 31-40 (2016).
- 569 54. C. M. Kagawa, Blocking urinary electrolyte effects of desoxycorticosterone with
570 progesterone in rats. *Proc Soc Exp Biol Med* **99**, 705-707 (1958).
- 571 55. G. Wambach, J. R. Higgins, Antimineralocorticoid action of progesterone in the rat:
572 correlation of the effect on electrolyte excretion and interaction with renal
573 mineralocorticoid receptors. *Endocrinology* **102**, 1686-1693 (1978).
- 574 56. J. W. Funder, W. R. Adam, 19-Nor progesterone is a mineralocorticoid agonist.
575 *Endocrinology* **109**, 313-315 (1981).
- 576 57. C. E. Hall, C. E. Gomez-Sanchez, S. Hungerford, E. P. Gomez-Sanchez,
577 Mineralocorticoid and hypertensive effects of 19-nor-progesterone. *Endocrinology*
578 **109**, 1168-1175 (1981).
- 579 58. B. Li, C. N. Dewey, RSEM: accurate transcript quantification from RNA-Seq data
580 with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).
- 581 59. L. Fagerberg, B. M. Hallstrom, P. Oksvold, C. Kampf, D. Djureinovic, J. Odeberg, M.
582 Habuka, S. Tahmasebpour, A. Danielsson, K. Edlund, A. Asplund, E. Sjostedt, E.
583 Lundberg, C. A. Szigartyo, M. Skogs, J. O. Takanen, H. Berling, H. Tegel, J. Mulder,
584 P. Nilsson, J. M. Schwenk, C. Lindskog, F. Danielsson, A. Mardinoglu, A. Sivertsson,
585 K. von Feilitzen, M. Forsberg, M. Zwahlen, I. Olsson, S. Navani, M. Huss, J. Nielsen,
586 F. Ponten, M. Uhlen, Analysis of the human tissue-specific expression by
587 genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell*
588 *Proteomics* **13**, 397-406 (2014).
- 589 60. A. H. Payne, D. B. Hales, Overview of steroidogenic enzymes in the pathway from
590 cholesterol to active steroid hormones. *Endocr Rev* **25**, 947-970 (2004).
- 591 61. K. N. Wynne, J. Mercer, J. R. Stockigt, J. W. Funder, 19-nor analogs of adrenal
592 steroids: mineralocorticoid and glucocorticoid receptor activity. *Endocrinology* **107**,
593 1278-1280 (1980).
- 594 62. S. Aquila, F. De Amicis, Steroid receptors and their ligands: effects on male gamete
595 functions. *Exp Cell Res* **328**, 303-313 (2014).
- 596 63. O. M. Conneely, B. Mulac-Jericevic, F. DeMayo, J. P. Lydon, B. W. O'Malley,
597 Reproductive functions of progesterone receptors. *Recent Prog Horm Res* **57**, 339-355
598 (2002).
- 599 64. E. R. de Kloet, C. Otte, R. Kumsta, L. Kok, M. H. Hillegers, H. Hasselmann, D.
600 Kliegel, M. Joels, Stress and Depression: a Crucial Role of the Mineralocorticoid
601 Receptor. *J Neuroendocrinol* **28**, (2016).
- 602 65. J. W. Funder, Aldosterone and mineralocorticoid receptors in the cardiovascular

603 system. *Prog Cardiovasc Dis* **52**, 393-400 (2010).

604 66. M. J. Young, A. J. Rickard, Mineralocorticoid receptors in the heart: lessons from
605 cell-selective transgenic animals. *J Endocrinol* **224**, R1-13 (2015).

606 67. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. *Nat*
607 *Methods* **9**, 357-359 (2012).

608 68. K. Oka, S. Kohno, H. Urushitani, L. J. Guillette, Jr., Y. Ohta, T. Iguchi, Y. Katsu,
609 Molecular cloning and characterization of the corticoid receptors from the American
610 alligator. *Molecular and cellular endocrinology* **365**, 153-161 (2013).

611 69. K. Oka, A. Hoang, D. Okada, T. Iguchi, M. E. Baker, Y. Katsu, Allosteric role of the
612 amino-terminal A/B domain on corticosteroid transactivation of gar and human
613 glucocorticoid receptors. *J Steroid Biochem Mol Biol* **154**, 112-119 (2015).

614